“Medicare Part B patients and American taxpayers have paid significantly more for prescription medications than people in comparable countries,” said Dr. Mehmet Oz, the administrator of the Centers for Medicare & Medicaid Services, as the agency finalized a new payment model on September 30. The model is mandatory and reaches about 25 percent of beneficiaries whose primary coverage is Original Medicare, chosen by where they live rather than by choice.
What CMS finalized on September 30
The agency’s press release names the program the Global Benchmark for Efficient Drug Pricing Model, shortened to GLOBE. It applies to separately payable Medicare Part B drugs and biological products, which the release describes as “medications typically administered by clinicians in health care settings.” Prices are set using international drug pricing information from economically comparable countries.
Mandatory is the operative word. The release says participation is required in a randomly selected subset of geographic areas, which together hold “approximately 25% of total Medicare beneficiaries who have Original Medicare as their primary coverage.” The denominator matters. The share is a quarter of the people for whom Original Medicare is the main payer, not a quarter of every Medicare enrollee. A beneficiary in Medicare Advantage, where a private plan is the primary coverage, is outside that count.
A model built on geography, not choice
A person in a selected area cannot opt out by picking a different doctor within Original Medicare. The release describes the areas as randomly selected, a design that lets the agency compare selected areas with others. The press release does not publish the list of areas in the text read for this article, and it does not say how a beneficiary can learn whether the local area is included.
That leaves a practical gap for households. A retiree on Original Medicare who takes an infused or injected drug has no way, from the release alone, to tell whether the model applies. The Federal Register notice and CMS model materials are where the area details would be expected to appear, and the practical step for now is to watch for them. A patient or caregiver can also ask the treating clinic’s billing office whether its drug claims will be priced under the model once January arrives, since the clinic is the party that submits them.
The calendar: 2027 start, April 1 effect, 2032 end
The model runs from January 1, 2027 to March 31, 2032, with reconciliation continuing through March 31, 2034. That is five years and three months of operation, followed by two more years of settling accounts. For beneficiaries, the release sets a later date than the model’s start. In its words, “selected beneficiaries who will be impacted by the model may begin to see reduced out of pocket costs beginning April 1, 2027.”
The phrasing is conditional on purpose. The release says beneficiaries “may begin to see” lower costs, and it puts no dollar figure on the savings. No estimate of what a typical patient will pay differently appears in it. Anyone reading a savings number attached to GLOBE is reading something CMS did not publish in this announcement.
Why Part B drug costs are the place to look
Medicare.gov’s page on outpatient prescription drugs explains why a Part B pricing change touches household budgets. Part B “covers most injectable and infused drugs when a licensed medical provider gives them,” and “after you meet the Part B deductible, you pay up to 20% of the Medicare-approved amount for Part B drugs.” A coinsurance share is tied to the approved amount, so a model that changes how an approved amount is benchmarked is the kind of change that can move a patient’s share.
The release itself does not walk through that arithmetic. It does not say how a 20 percent share would change under the benchmark, and the fact that a quarter of beneficiaries are covered does not tell any one household that its own bills will fall.
What the release leaves out: excluded drugs and the rule text
CMS lists four exclusions: biosimilars once market entry occurs, orphan-only drugs, plasma-derived products and certain cell and gene therapies. A patient on one of those would sit outside the model even in a selected area.
The rule itself was made public the same day. The Office of the Federal Register’s public inspection listing, document number 2026-20281, shows a rule filed September 30, 2026 at 4:15 pm, running 585 pages, with publication scheduled for October 2, 2026. The listing carries the document’s metadata, and the full 585-page text was not available on that page. Until the notice is published and its text read, the press release is the official summary and the Federal Register filing is the official record to watch.
The date to keep in mind for a household budget is April 1, 2027, the first day the release says lower out-of-pocket costs may appear. Nothing on either page changes what beneficiaries pay before January 1, 2027, and nothing in CMS’s release points to a change in Part D, the drug plans that cover pills filled at a pharmacy.
Keeping Part B drug bills straight while the model phases in
A change to how Part B drugs are priced would show up on infusion and injection bills, where the coinsurance share is set against an approved amount. A household cannot tell from the announcement alone whether its own area is in the model, so the bills themselves are the evidence.
The Medicare Cost & Coverage Protection Kit includes a medication and cost tracker and the prior-authorization appeal steps, which cover logging each treatment and responding when a drug is denied.
Start with The Medicare Cost & Coverage Protection Kit →
This piece was produced with AI assistance and checked against the CMS, Federal Register and Medicare.gov pages linked above.
